# Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)

> **NCT00040534** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 22 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Farnesyl Protein Transferase Inhibitor

## Key facts

- **NCT ID:** NCT00040534
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-01
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040534, "Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00040534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*